Venetoclax tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Venclexta / Venclyxto
- Company
- AbbVie Inc. (US label); AbbVie Deutschland GmbH & Co. KG (EU authorization holder)
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- US prescribing information: adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. Also, with azacitidine, decitabine or low-dose cytarabine, for newly diagnosed acute myeloid leukemia in adults aged 75 years or older, or adults with comorbidities that prevent intensive induction chemotherapy. These are US indications, not verification of Chinese labeling.
- Indication source and scope
- Revised 05/2026. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval, current Chinese indications and continuous market availability were not independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208573s032lblCorrected.pdf
- Venclexta — US full prescribing information
Official prescribing information · Revised 05/2026
Complete FDA-hosted label opened; indications and BCL-2 mechanism checked. US scope does not establish Chinese approval.
- Venclexta / Venclyxto — EMA European public assessment report
Regulatory medicine overview · Web page accessed 2026-11-02
English primary regulatory source opened and reviewed. Selected EU indications and the EU authorization holder are reported; this is not evidence of Chinese approval.
Evidence reviewed:
Open the interactive record, public price references and discussions